Merck CEO Says Drug-Price Debate Doesn't Account for R&D Risks
- Competition eventually cuts into drug profits, Frazier says
- Doesn't see tax inversion merger as best path for Merck
This article is for subscribers only.
Talking drug prices with President Barack Obama was just the start. Merck & Co.’s chief executive officer says he’s on a campaign to change a perception most Americans have: that pharmaceutical companies charge too much for their drugs.
Ken Frazier has been roaming the halls of Washington, a short trip from Merck headquarters in New Jersey, to make the case that the drug industry relies on a few precious years of high prices to fund research before its medications lose their patents.